CN1290838C - Sulfonated derivative of andrographolide and combination of medication - Google Patents

Sulfonated derivative of andrographolide and combination of medication Download PDF

Info

Publication number
CN1290838C
CN1290838C CNB2005100385611A CN200510038561A CN1290838C CN 1290838 C CN1290838 C CN 1290838C CN B2005100385611 A CNB2005100385611 A CN B2005100385611A CN 200510038561 A CN200510038561 A CN 200510038561A CN 1290838 C CN1290838 C CN 1290838C
Authority
CN
China
Prior art keywords
compound
andrographolide
general formula
sulfonated derivative
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2005100385611A
Other languages
Chinese (zh)
Other versions
CN1687049A (en
Inventor
唐春山
叶文才
胡永美
杨小玲
Original Assignee
唐春山
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 唐春山 filed Critical 唐春山
Priority to CNB2005100385611A priority Critical patent/CN1290838C/en
Publication of CN1687049A publication Critical patent/CN1687049A/en
Application granted granted Critical
Publication of CN1290838C publication Critical patent/CN1290838C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了具有抗菌、消炎、解热作用的11种穿心莲内酯磺化衍生物及含有它们的药物组合物，其疗效显著、化学性质稳定、水溶性好，质量标准明确可控，用于制备冻干粉针、注射液或口服制剂，治疗肺炎、支气管炎、扁桃体炎、细菌性痢疾等疾病。The invention discloses 11 kinds of andrographolide sulfonated derivatives with antibacterial, anti-inflammatory and antipyretic effects and a pharmaceutical composition containing them. The curative effect is remarkable, the chemical properties are stable, the water solubility is good, and the quality standard is clear and controllable. Prepare freeze-dried powder, injection or oral preparations to treat pneumonia, bronchitis, tonsillitis, bacillary dysentery and other diseases.

Description

Sulfonated derivative of andrographolide and pharmaceutical composition thereof
Technical field
The present invention relates to have the sulfonated derivative of andrographolide of antibiotic, anti-inflammatory, refrigeration function and contain their pharmaceutical composition.
Background technology
Herba Andrographis (Andrographis paniculata (Burm.f.) Nees) is Acanthaceae Herba Andrographis platymiscium, calls Herba Andrographitis, cuts snakeweed, eel grass, olive lotus, originates in India, and areas such as Fujian, China Guangdong are extensively cultivation also.Chemistry and pharmacological evaluation show the activeconstituents of Herba Andrographis for being the diterpene-kind compound and the glucoside derivative of representative with the rographolide, and the rographolide structure is:
Figure C20051003856100041
Molecular formula: C 20H 30O 5, be colourless square or rectangle crystallization, m.p.230-232 ℃, [α] D 20-126 ° of (c0.2, H 2O).Flavor is extremely bitter, dissolves in methyl alcohol, ethanol, propyl alcohol, the pyridine, is slightly soluble in chloroform, ether, is insoluble in water and sherwood oil.Water insoluble because of rographolide, brought difficulty for the preparation injection liquid.At present, existing several different methods is used to transform rographolide and becomes various derivatives, to improve the water-soluble of rographolide.The present application people once applied for " sulfonation process of water soluble andrographolide " (patent No. ZL01131382.x.), wherein the structure identification to sulfonated derivative of andrographolide is wrong, in fact the total sulfonated bodies that generates after the rographolide sulfonation is a mixture, thereby be difficult to formulate quality standard, and have influence on the quality control of product.
Summary of the invention
The technical problem to be solved in the present invention is in the mixture (being total sulfonated bodies) how to obtain from " sulfonation process of water soluble andrographolide " (patent No. ZL01131382.x.), isolate the various derivatives that generate after the rographolide sulfonation, be the various sulfonated derivatives of rographolide, identify its chemical structure, study and filter out and have excellent antibacterial, anti-inflammatory, the sulfonated derivative of andrographolide that the structure of refrigeration function is clear and definite, comprise the mixture of forming by the clear and definite sulfonated derivative of andrographolide of structure, and contain they and the pharmaceutical composition of available support pharmaceutically.
For addressing the above problem, the invention provides following technical scheme:
Sulfonated derivative of andrographolide or its mixture of following general formula (I), (II) expression:
Figure C20051003856100051
General formula (I)
R in the general formula (I) 1, R 2Be selected from independently of one another-H ,-SO 3H; R 3During for hydroxyl, R 4For-ONa, perhaps R 3=R 4=-O-;
General formula (II)
R in the general formula (II) 1, R 2Be selected from independently of one another-H ,-SO 3H; R 3Be the H of R body or the H of S body; R 4Methyl for the S body.
The mixture of described general formula (I), (II) sulfonated derivative of andrographolide is meant the sulfonated derivative of andrographolide assembly arbitrarily of general formula (I), (II) expression, promptly be selected from the sulfonated derivative of andrographolide of general formula (I), (II) expression two or more, can reach 11 kinds.
Aforementioned formula (I), (II) sulfonated derivative of andrographolide or its mixture, wherein
General formula (I)
R 1 R 2 R 3 R 4
Compound 1 compound 2 compounds 3 compounds 4 compounds 5 H SO 3H SO 3H H SO 3H SO 3H H SO 3H SO 3H H OH OH ONa ONa R 3＝R 4 O O O
Figure C20051003856100072
General formula (II)
Figure C20051003856100073
Above-mentioned general formula (I), (II) sulfonated derivative of andrographolide or its mixture, wherein mixture is meant two or more mixture in the sulfonated derivative of andrographolide that is selected from general formula (I), (II) expression.Wherein mixture is meant two or more mixture that is selected from compound 1, compound 4, compound 5, the compound 8 preferably.
The pharmaceutical composition of general formula of the present invention (I), (II) sulfonated derivative of andrographolide or its mixture mainly is made up of general formula (I), (II) sulfonated derivative of andrographolide or its mixture and pharmaceutically acceptable carrier.
The pharmaceutical composition of general formula of the present invention (I), (II) sulfonated derivative of andrographolide or its mixture mainly is made up of general formula (I), (II) sulfonated derivative of andrographolide or its mixture and water for injection.
The pharmaceutical composition of general formula of the present invention (I), (II) sulfonated derivative of andrographolide or its mixture mainly is made up of general formula (I), (II) sulfonated derivative of andrographolide or its mixture and N.F,USP MANNITOL freeze-dried powder auxiliary material.
The pharmaceutical composition of general formula of the present invention (I), (II) sulfonated derivative of andrographolide or its mixture mainly is made up of general formula (I), (II) sulfonated derivative of andrographolide or its mixture and oral preparations auxiliary material.
The invention provides new sulfonated derivative of andrographolide, provide the pharmaceutical composition that contains them antibiotic simultaneously in preparation, anti-inflammatory, analgesic, the application in the antiviral.
The present invention is raw material with the rographolide, take process for sulfonation, prepared a series of new sulfonated derivative of andrographolide, these sulfonated bodies derivant structures are clear and definite, have good antibiotic, anti-inflammatory, analgesic, antiviral activity is made clear and definite, quality controllable, the preparation stabilization of Chemical Composition behind all kinds of preparations, to pneumonia, upper respiratory tract infection such as bronchitis have good therapeutic action.Compare with rographolide and the total sulfonated bodies of rographolide, these sulfonated derivative of andrographolide water solubility of monomer are good, purity is high, and quality controllable.
The present invention includes from the total sulfonated bodies of rographolide to separate and obtain above-mentioned 11 kinds of sulfonated derivative of andrographolide, be the new constituent that obtains first, have good water-solubility, stability, can be made into various preparations, be particularly useful for preparing intravenous injection.11 kinds of sulfonated derivative of andrographolide all have good antibiotic, anti-inflammatory, refrigeration function.
The preparation method of the total sulfonated bodies of rographolide is referring to the separation of patent of invention ZL01131382.x. sulfonated derivative of andrographolide, purification process: get the total sulfonated bodies 50g of rographolide, add water 50mL and make dissolving fully, filter, the D101 type macroporous resin column of anticipating on the sample liquid, water successively, 10%, 20%, 30%, 40%, 50%, 80%, 90% ethanol carries out gradient elution, tentatively be divided into six sections [F1 (10%), F2 (20%), F3 (30%), F4 (40%-50%), F5 (80%), F6 (90%)] silica gel H on the back, ODS (reversed-phase column) and Sephadex LH-20 (gel) post etc. carry out separation and purification, finally obtain 11 compounds.The F1 section is by the ODS post, and 20%～25% methyl alcohol carries out wash-out, gets compound 1 (rographolide 19-sulfuric ester, 16-carboxylic acid sodium salt) and compound 2 (rographolide 3-sulfuric ester, 16-carboxylic acid sodium salt); The F2 section is by the ODS post, and the methyl alcohol with 30%～40% carries out getting compound 3 (3,19-di-sulfate rographolide) and compound 5 (3-sulfuric ester rographolide) behind the wash-out; The F3 section goes up the silica gel H post for three times repeatedly with chloroform-methanol (6: 1) separates, and carries out purifying through Sephadex LH-20, gets compound 4 (19-sulfuric ester rographolide); F5 and F6 section are carried out silica gel column chromatography three times repeatedly with chloroform-methanol (9: 1), get compound 6 (8 (12)-epoxy rographolide (8S, 12S)) and compound 9 (8 (12)-epoxy rographolide (8S, mixture 12R)), the compound 6 that is prepared through HPLC and the pure product of compound 9 again; After concentrating, the F4 section separates three times with the silica gel H post repeatedly, carry out wash-out with chloroform-methanol (6: 1～4: 1), carry out purifying through Sephadex LH-20, and prepare the type post in conjunction with HPLC and be prepared, final compound 7 (8 (12)-epoxies, the 19-sulfuric ester, rographolide (8S, 12S)), compound 8 (8 (12)-epoxies, the 3-sulfuric ester, rographolide (8S, 12S)), compound 10 (8 (12)-epoxies, the 19-sulfuric ester, rographolide (8S, 12R)) and compound 11 (8 (12)-epoxies, 3-sulfuric ester, rographolide (8S, 12R)).
Embodiment
Embodiment 1
Prepare the total sulfonated bodies of rographolide (referring to ZL01131382.x.) with the rographolide process for sulfonation:.
The extraction of rographolide:
Get Herba Andrographis 1000g, add the ethanol 5000ml of 90% above concentration, cold soaking, 72 hours for the first time, 24 hours for the second time, cooling bath is evacuated in the return tank, press the Folium Andrographis charging capacity and calculate, add the 15-18% gac, refluxed 2 hours; Liquid filtering behind the reflux decolour, filtrate is concentrated into when 10% left and right sides ethanol is still arranged and emits, crystallization in static 24 hours, with coarse crystallization ethanol successive soaking twice, each time was not less than 6 hours, filtered, crystallization is added 8 times of amount ethanol, after the heating for dissolving, filtered in static 24 hours white crystals, crystallization vacuum-drying is got rographolide.
The sulfonation of rographolide:
Get dehydrated alcohol 1000ml, put in the reaction flask, slowly drip sulfuric acid 600ml, after stirring evenly, add the 1000g rographolide, stir, room temperature was placed 72 hours.Put adding ethanol 1000ml in the water-bath, stir evenly, transfer pH to 7.0, add ethanol, reach 80% to containing the alcohol amount, static 24 hours, the adding small amount of activated was filtered, and filtrate recycling ethanol is condensed into thick paste, and vacuum-drying promptly gets total sulfonated bodies of rographolide.
Embodiment 2
The separation of compound 1, compound 2, purifying
(high-efficient silica gel plate and silica gel H are that Haiyang Chemical Plant, Qingdao produces; C18 (ODS post) is Merck ﹠ Co., Inc.'s product; All reagent are analytical pure.Down together.)
Get the total sulfonated bodies 50g of rographolide and add water 50ml dissolving, filter the D101 macroporous resin column of anticipating on the back, water, 10%, 20%, 30%, 40%, 50%, 80%, 90% ethanol carry out gradient elution successively.
Get 10% ethanol eluate of D101 macroporous resin column, concentrate the back and go up the ODS post, use 20% methanol-eluted fractions earlier, use 25% methanol-eluted fractions again.
20% meoh eluate concentrates the back recrystallizing methanol, filters, and crystallization vacuum-drying (60 ℃) gets compound 1.25% meoh eluate concentrates the back recrystallizing methanol, filters, and crystallization vacuum-drying (60 ℃) gets compound 2.
The physico-chemical property of compound 1 and spectral data
The chemistry Chinese: 3,14,19-trihydroxy--8 (9), 12 (13)-labdanum diene-16-carboxylic acid sodium, 19-sulfuric ester.
Colourless needle (methyl alcohol) is soluble in methyl alcohol, water, is slightly soluble in acetone, is insoluble to chloroform, ether and sherwood oil.
Molecular formula: C 20H 31O 8SNa, molecular weight: 493.11; Mp:230-232 ℃; [α] D 24:-62.0 (c 0.1, MeOH).
ESI-MS：493[M+Na] +
1H-NMR(CD 3OD)δ：6.45(1H，dd，J＝4.8Hz，7.8Hz，H-12)，4.58(1H，dd，J＝4.8Hz，7.5Hz，H-14)，3.67(1H，dd，J＝11.1，7.7Hz，H-15)，3.50(1H，dd，J＝11.1，4.9Hz，H-15)，4.18(2H，q，J＝10.2Hz，H-19)，3.25(1H，dd，J＝11.1，5.1Hz，H-3)，3.0(1H，dd，J＝17.3，7.9Hz，H-11)，2.73(1H，dd，J＝17.3，4.9Hz，H-11)，1.54(3H，s，H-17)，1.19(3H，s，H-18)，1.05(3H，s，H-20)
13C-NMR(CD 3OD)δ：19.7(C-17)，20.5(C-20)，21.2(C-6)，23.4(C-18)，27.4(C-11)，28.6(C-2)，35.7(C-7)，36.7(C-1)，40.0(C-10)，43.5(C-4)，53.7(C-5)，67.3(C-15)，70.9(C-19)，72.0(C-14)，80.0(C-3)，129.2(C-8)，134.8(C-13)，139.6(C-9)，141.5(C-12)，175.9(C-16).
The physico-chemical property of compound 2 and spectral data
The chemistry Chinese: 3,14,19-trihydroxy--8 (9), 12 (13)-labdanum diene-16-carboxylic acid sodium, 3-sulfuric ester
Colourless needle (methyl alcohol) is soluble in methyl alcohol, water, is slightly soluble in acetone, is insoluble to chloroform, ether and sherwood oil.
Molecular formula: C 20H 31O 8SNa, molecular weight: 493.11; Mp:242-244 ℃; [α] D 24:-53.0 (c 0.1, MeOH).
ESI-MS：493[M+Na] +
1H-NMR(CD 3OD)δ：6.46(1H，dd，J＝4.8Hz，7.8Hz，H-12)，4.60(1H，dd，J＝2.8Hz，9.0Hz，H-14)，4.16(2H，q，J＝6Hz，H-19)，3.67(1H，dd，J＝11.1，7.7Hz，H-15)，3.50(1H，dd，J＝11.1，4.9Hz，H-15)，3.26(1H，dd，J＝11.1，4.6Hz，H-3)，3.0(1H，dd，J＝10.4，4.8Hz，H-11)，2.73(1H，dd，J＝10.4，2.8Hz，H-11)，1.54(3H，s，H-17)，1.20(3H，s，H-18)，1.05(3H，s，H-20)；
13C-NMR(CD 3OD)δ：19.7(C-17)，20.6(C-20)，21.2(C-6)，23.3(C-18)，27.4(C-11)，28.6(C-2)，35.7(C-7)，36.7(C-1)，39.9(C-10)，43.4(C-4)，54.0(C-5)，67.1(C-15)，70.8(C-19)，72.0(C-14)，88.1(C-3)，129.3(C-8)，134.6(C-13)，139.5(C-9)，141.5(C-12)，175.9(C-16).
Embodiment 3
The separation of compound 3, compound 5, purifying
Get the ethanol eluate of D101 macroporous resin column 20% among the embodiment 2, concentrate the back and go up the ODS post, use 30% methanol-eluted fractions earlier, use the 35-40% methanol-eluted fractions again.30% meoh eluate concentrates the back recrystallizing methanol, filters, and crystallization vacuum-drying (60 ℃) gets compound 3.
The 35-40% meoh eluate concentrates the back recrystallizing methanol, filters, and crystallization vacuum-drying (60 ℃) gets compound 5.
The physico-chemical property of compound 3 and spectral data
The chemistry Chinese: 3,14,19-trihydroxy--8 (9), 12 (13)-labdanum diene-15,16-lactone-19-sulfuric ester.
Colourless needle (methyl alcohol) is soluble in methyl alcohol, water, is slightly soluble in acetone, is insoluble to chloroform, ether and sherwood oil.
Molecular formula: C 20H 30O 11S 2, molecular weight: 510; Mp:251-253 ℃; [α] D 24:-27.0 (c 0.1, MeOH).
IR max KBrcm -1：3437(OH)，1759，1669(C＝C-C＝O)，1630，1637(C＝C)，1293，1254，1204，1068，995，972，436，418；
ESI-MS：511[M+H] +，350[M-SO 3H] +，430[M-SO 3H-SO 3H] +；
1H-NMR(CD 3OD)δ：6.74(1H，m，H-12)，5.07(1H，dd，J＝1.4Hz，4.5Hz，H-14)，4.49(1H，dd，J＝10.2，6.2Hz，H-15)，4.15(1H，dd，J＝10.2，2.3Hz，H-15)，4.36(1H，d，J＝10.1Hz，H-19)，4.05(1H，d，J＝10.1Hz，H-19)，4.0(1H，dd，J＝12.2，4.4Hz，H-3)，3.27(1H，dd，J＝17.7Hz，4.9Hz，H-11)，3.12(1H，dd，J＝17.7，5.0Hz，H-11)，1.62(3H，s，H-17)，1.27(3H，s，H-18)，1.17(3H，s，H-20).
13C-NMR(CD 3OD)δ：19.8(C-17)，20.2(C-20)，21.8(C-6)，23.6(C-18)，25.8(C-2)，29.2(C-11)，35.8(C-7)，36.6(C-1)，40.0(C-10)，43.0(C-4)，54.0(C-5)，66.8(C-14)，71.0(C-19)，76.0(C-15)，86.8(C-3)，129.1(C-13)，130.5(C-8)，138.0(C-9)，149.5(C-12)，172.7(C-16)
The physico-chemical property of compound 5 and spectral data
The chemistry Chinese: 3,14,19-trihydroxy--8 (9), 12 (13)-labdanum diene-15,16-lactone-3-sulfuric ester.
Colourless needle (methyl alcohol) is soluble in methyl alcohol, water, is slightly soluble in acetone, is insoluble to chloroform, ether and sherwood oil.
Molecular formula: C 20H 30O 8S, molecular weight: 430; Mp:159-161 ℃; [α] D 24:-36.0 (c 0.1, MeOH).
IR max KBrcm -1：3414(OH)，1749，1670(C＝C-C＝O)，1470，1427(C＝C)，1254，1230，1218，1197，1060，1033，966，981，，922，832，582；
ESI-MS：429[M-H] +，349[M-SO 3H] +，412[M-H 2O] +；
1H-NMR(CD 3OD)8：6.72(1H，m，H-12)，5.06(1H，dd，J＝1.4Hz，4.5Hz，H-14)，4.49(1H，dd，J＝10.2，6.2Hz，H-15)，4.15(1H，dd，J＝10.2，2.3Hz，H-15)，4.36(1H，d，J＝10.1Hz，H-19)，4.05(1H，d，J＝10.1Hz，H-19)，4.04(1H，dd，J＝11.8，4.4Hz，H-3)，3.26(1H，dd，J＝17.6Hz，5.2Hz，H-11)，3.10(1H，dd，J＝17.6，5.0Hz，H-11)，1.61(3H，s，H-17)，1.22(3H，s，H-18)，1.03(3H，s，H-20).
13C-NMR(CD 3OD)δ：19.8(C-17)，20.6(C-20)，20.7(C-6)，23.1(C-18)，25.7(C-2)，29.0(C-11)，35.4(C-7)，36.3(C-1)，39.8(C-10)，44.3(C-4)，53.9(C-5)，64.1(C-14)，66.9(C-19)，76.0(C-15)，87.9(C-3)，129.2(C-13)，130.4(C-8)，137.9(C-9)，149.3(C-12)，172.6(C-16).
Embodiment 4
The separation of compound 4, purifying
Get the ethanol eluate of D101 macroporous resin column 30% among the embodiment 2, go up the silica gel H post after concentrating repeatedly for three times and separate, eluting solvent is chloroform-methanol (6: 1), carries out purifying through Sephadex LH-20 again, and recrystallizing methanol gets compound 4.
The physico-chemical property of compound 4 and spectral data
The chemistry Chinese: 3,14,19-trihydroxy--8 (9), 12 (13)-labdanum diene-15,16-lactone-19-sulfuric ester.
Off-white color or pale yellow powder are soluble in methyl alcohol, water, are slightly soluble in acetone, are insoluble to chloroform, ether and sherwood oil.
Molecular formula: C 20H 30O 8S, molecular weight: 430; Mp:166-168 ℃; [α] D 24:-48.0 (c 0.1, MeOH).
UVλ max MeOH nm：227；
IR max KBrcm -1：3431(OH)，1734，1636(C＝C-C＝O)，1541，1457(C＝C)，1214，1070，983，436，418；
ESI-MS：429[M-H] +，349[M-SO 3H] +，412[M-H 2O] +；
1H-NMR(CD 3OD)δ：6.74(1H，m，H-12)，5.06(1H，d，J＝4.8Hz，H-14)，4.48(1H，dd，J＝10.2，6.2Hz，H-15)，4.15(1H，dd，J＝10.2，2.3Hz，H-15)，3.20(1H，dd，J＝17.6，5.0Hz，H-11)，3.08(1H，dd，J＝17.6，5.2Hz，H-11)，1.60(3H，s，H-17)，1.14(3H，s，H-18)，1.10(3H，s，H-20).
13C-NMR(CD 3OD)δ：19.9(C-17)，20.5(C-20)，21.2(C-6)，23.4(C-18)，28.6(C-2)，29.1(C-11)，35.7(C-7)，36.8(C-1)，40.0(C-10)，43.5(C-4)，53.6(C-5)，66.9(C-14)，71.0(C-19)，76.1(C-15)，79.8(C-3)，129.2(C-13)，130.5(C-8)，138.1(C-9)，149.6(C-12)，172.7(C-16).
Embodiment 5
The separation of compound 6, compound 9, purifying
Get the ethanol eluate of D101 macroporous resin column 80%～90% among the embodiment 2, concentrate the back and make eluting solvent with chloroform-methanol (9: 1), carry out silica gel column chromatography three times repeatedly, elutriant is prepared through HPLC again, and chromatographic condition is: chromatographic column: phe-nomenex C18-ODS (250mm * 10.0mm 5 μ m); Moving phase is: methyl alcohol: water (30: 70), flow velocity: during 2ml/min, be prepared into compound 6; Moving phase is: methyl alcohol: water (45: 55), flow velocity: during 2ml/min, be prepared into compound 9.
The physico-chemical property of compound 6 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15,16-lactone.
Colourless needle is soluble in methyl alcohol, acetone, is slightly soluble in chloroform, is insoluble to ether and sherwood oil.
Molecular formula: C 20H 30O 5, molecular weight: 350.1; Mp:210-212 ℃; [α] D 24:-16.4 (c 0.1, MeOH).
IR max KBrcm -1：3489，3425cm -1(OH)，1758，1650cm -1，(C＝C-C＝O)，1450，1380(C＝C)，1223，1196，1083，1031，1019，988，963，846；
ESI-MS：349[M-H] +，301[M-CH 2OH-H 2O] +，257[M-H 2O-CH 2OH-CO 2] +；
1H-NMR(CD 3OD)δ：7.43(1H，t，J＝1.5Hz，H-14)，4.85(2H，m，H-15)，4.80(1H，t，J＝6.7Hz，H-12)，4.03(1H，d，J＝11.1Hz，H-19)，3.46(1H，d，J＝11.1Hz，H-19)，3.21(1H，dd，J＝4.7，11.9Hz，H-3)，2.18(1H，dd，J＝11.3，12.2Hz，H-11)，1.64(1H，t，J＝10.2Hz，H-11)，1.20(3H，s，H-18)，
1.19(3H，s，H-17)，0.90(3H，s，H-20).
13C-NMR(CD 3OD)δ：39.1(C-1)，28.3(C-2)，81.2(C-3)，43.7(C-4)，57.7(C-5)，22.0(C-6)，41.1(C-7)，83.3(C-8)，59.4(C-9)，37.0(C-10)，29.7(C-11)，72.0(C-12)，137.1(C-13)，148.4(C-14)，72.4(C-15)，174.8(C-16)，21.8(C-17)，23.5(C-18)，65.0(C-19)，15.9(C-20).
The physico-chemical property of compound 9 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15, the 16-lactone is a white powder, soluble in water, methyl alcohol is slightly soluble in acetone, is insoluble to ether and sherwood oil.
Molecular formula: C 20H 30O 8S, molecular weight: 430;
1H-NMR(CD 3OD)δ：7.46(1H，m，H-14)，4.86(2H，m，H-15)，4.60(1H，m，H-12)，3.80(1H，d，J＝11.2Hz，H-19)，3.60(1H，d，J＝11.2Hz，H-19)，4.03(1H，m，H-3)，1.22(3H，s，H-18)，1.13(3H，s，H-17)，1.0(3H，s，H-20).
13C-NMR(CD 3OD)δ：40.3(C-1)，25.1(C-2)，87.9(C-3)，44.3(C-4)，54.3(C-5)，37.2(C-6)，19.8(C-7)，84.3(C-8)，58.0(C-9)，36.8(C-10)，33.8(C-11)，72.3(C-12)，138.4(C-13)，147.0(C-14)，74.2(C-15)，175.0(C-16)，31.9(C-17)，23.4(C-18)，64.0(C-19)，16.6(C-20).
Embodiment 6
The separation of compound 7, compound 8, purifying
Get 40%～50% ethanol eluate of D101 macroporous resin column among the embodiment 2, go up the silica gel H post three times repeatedly after concentrating, all use chloroform-methanol (6: 1～4: 1) to carry out gradient elution at every turn, carry out purifying through Sephadex LH-20, get the mixture of compound 7,8, be prepared through HPLC again, chromatographic condition: chromatographic column: Waters Novapak C18 (40mm * 150mm.6 μ m), moving phase is methyl alcohol: water: during phosphoric acid (30: 70: 0.2), get compound 7; Moving phase is methyl alcohol: water: during phosphoric acid (40: 60: 0.2), get compound 8.
The physico-chemical property of compound 7 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15,16-lactone-19 sulfuric ester.
Colourless needle, soluble in water, methyl alcohol is slightly soluble in acetone, is insoluble to ether and sherwood oil
Molecular formula: C 20H 30O 8S, molecular weight: 430; Mp:255-257 ℃; [α] D 24:-18.4 (c 0.1, MeOH).
ESI-MS：429[M-H] +，301[M-CH 2OH-H 2O-SO 3H] +；
1H-NMR(CD 3OD)δ：7.43(1H，t，J＝1.5Hz，H-14)，4.85(2H，m，H-15)，4.83(1H，m，H-12)，4.20(1H，d，J＝10.2Hz，H-19)，4.15(1H，d，J＝10.2Hz，H-19)，3.21(1H，dd，J＝4.7，11.9Hz，H-3)，1.22(3H，s，H-18)，1.18(3H，s，H-17)，1.0(3H，s，H-20).
13C-NMR(CD 3OD)δ：39.5(C-1)，27.9(C-2)，80.0(C-3)，43.5(C-4)，57.9(C-5)，23.0(C-6)，41.4(C-7)，83.5(C-8)，59.5(C-9)，37.1(C-10)，29.7(C-11)，71.9(C-12)，137.2(C-13)，148.5(C-14)，72.4(C-15)，174.9(C-16)，21.6(C-17)，23.3(C-18)，71.0(C-19)，15.5(C-20).
The physico-chemical property of compound 8 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15,16-lactone-3 sulfuric ester.
Be white powder, soluble in water, methyl alcohol is slightly soluble in acetone, is insoluble to ether and sherwood oil.
Molecular formula: C 20H 30O 8S, molecular weight: 430;
1H-NMR(CD 3OD)δ：7.43(1H，m，H-14)，4.86(2H，m，H-15)，4.56(1H，m，H-12)，4.03(1H，m，H-19)，3.60(1H，d，J＝11.1Hz，H-19)，4.56(1H，m，H-3)，1.20(3H，s，H-18)，1.19(3H，s，H-17)，0.93(3H，s，H-20) 13C-NMR(CD 3OD)δ：39.1(C-1)，25.1(C-2)，88.2(C-3)，44.3(C-4)，58.1(C-5)，23.2(C-6)，41.1(C-7)，83.2(C-8)，59.1(C-9)，36.8(C-10)，29.7(C-11)，71.9(C-12)，137.2(C-13)，148.4(C-14)，72.4(C-15)，174.8(C-16)，21.6(C-17)，23.4(C-18)，64.0(C-19)，15.3(C-20).
Embodiment 7
The separation of compound 10, compound 11, purifying
Get 40%～50% ethanol eluate of D101 macroporous resin column among the embodiment, go up the silica gel H post three times repeatedly after concentrating, carry out gradient elution with chloroform-methanol (6: 1～4: 1), elutriant prepares the type post through HPLC and carries out purifying, chromatographic condition: chromatographic column Waters Novapak C18 (40mm * 150mm.6 μ m) is a water with moving phase earlier: acetonitrile: 0.05M phosphoric acid (58: 12: 30); It is water with moving phase again: acetonitrile: 0.05M phosphoric acid (30: 40: 30).
Moving phase is water: acetonitrile: during 0.05M phosphoric acid (58: 12: 30), get compound 10; Moving phase is water: acetonitrile: during 0.05M phosphoric acid (30: 40: 30), get compound 11.
The physico-chemical property of compound 10 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15,16-lactone.
Colourless needle is soluble in methyl alcohol, acetone, is slightly soluble in chloroform, is insoluble to ether and sherwood oil.
Molecular formula: C 20H 30O 5, molecular weight: 350.1; Mp:210-212 ℃; [α] D 24:-21.4 (c 0.1, MeOH).
IR max KBrcm -1：3489，3425cm -1(OH)，1758，1650cm -1，(C＝C-C＝O)，1450，1380(C＝C)，1223，1196，1083，1031，1019，988，963，846；
ESI-MS：349[M-H] +，305[M-CO 2-H] +；
1H-NMR(CD 3OD)δ：7.46(1H，m，H-14)，4.85(2H，m，H-15)，4.66(1H，m，H-12)，4.05(1H，d，J＝11.1Hz，H-19)，3.46(1H，d，J＝11.1Hz，H-19)，3.35(1H，dd，J＝4.9，11.6Hz，H-3)，2.37(1H，dd，J＝13.2，6.8Hz，H-11)，2.07(1H，td，J＝10.2Hz，H-11)，1.22(3H，s，H-18)，1.13(3H，s，H-17)，1.0(3H，s，H-20).
13C-NMR(CD 3OD)δ：40.4(C-1)，28.4(C-2)，81.5(C-3)，43.5(C-4)，53.7(C-5)，37.2(C-6)，19.5(C-7)，84.4(C-8)，59.6(C-9)，36.9(C-10)，33.9(C-11)，74.3(C-12)，138.5(C-13)，146.5(C-14)，72.4(C-15)，175.0(C-16)，32.0(C-17)，23.5(C-18)，65.2(C-19)，17.0(C-20)..
The physico-chemical property of compound 11 and spectral data
The chemistry Chinese: 3,19-dihydroxyl-8 (12) epoxies-13 (14)-labdanum alkene-15,16-lactone.
Colourless needle, soluble in water, methyl alcohol is slightly soluble in acetone, is insoluble to ether and sherwood oil
Molecular formula: C 20H 30O 8S, molecular weight: 430; Mp:255-257 ℃; [α] D 24:-18.4 (c 0.1, MeOH).
IR max KBrcm -1：3489，3425cm -1(OH)，1758，1650cm -1，(C＝C-C＝O)；
ESI-MS：429[M-H] +，301[M-CH 2OH-H 2O-SO 3H] +，；
1H-NMR(CD 3OD)δ：7.41(1H，m，H-14)，4.84(2H，m，H-15)，4.64(1H，m，H-12)，4.28(1H，d，J＝11.2Hz，H-19)，3.14(1H，d，J＝11.2Hz，H-19)，3.24(1H，dd，J＝4.7，11.6Hz，H-3)，2.39(1H，dd，J＝13.2，6.8Hz，H-11)，2.07(1H，td，J＝10.2Hz，H-11)，1.20(3H，s，H-18)，1.13(3H，s，H-17)，1.0(3H，s，H-20)；
13C-NMR(CD 3OD)δ：40.4(C-1)，28.4(C-2)，81.5(C-3)，43.5(C-4)，53.7(C-5)，37.2(C-6)，19.5(C-7)，84.4(C-8)，59.6(C-9)，36.9(C-10)，33.9(C-11)，74.3(C-12)，138.5(C-13)，146.5(C-14)，72.4(C-15)，175.0(C-16)，32.0(C-17)，23.5(C-18)，65.2(C-19)，17.0(C-20)..
Embodiment 8
One, animal acute toxicity test
1. test objective: measure acute reaction and the death condition of the composition of compound 1,2,3,4,5,7,8, compound 4 and compound 5 through vein single administration mouse.
2. test materials:
2.1 trial drug
The composition of compound 1, compound 2, compound 3, compound 4, compound 5, compound 7, compound 8, compound 4 and compound 5, concentration is 0.1g/ml, is provided by Jiangxi QingFeng Pharmacy Co., Ltd.Lot number: 20030806.
2.2 animal subject
The ICR mouse, body weight 18-20g, male and female half and half are supplied with by Jiangxi QingFeng Pharmacy Co., Ltd's Experimental Animal Center.Laboratory animal occupancy permit number: SKYX (Jiangxi) 2003-0001
3. test conditions:
Before and after the administration, the experiment mice male and female are divided cage, and full-valence pellet feed is fed, and freely drinks water 20 ± 2 ℃ of room temperatures, humidity: 45%-65%.
4. test method and result:
4.1 method: get 180 of ICR mouse, body weight 18-20g, male and female half and half.Be divided into 9 groups at random, 20 every group.Control group: 0.9% sodium chloride injection.The composition of the compound 1 of sample sets: 100mg/ml, compound 2, compound 3, compound 4, compound 5, compound 7, compound 8, compound 4 and compound 5.Sample sets is once given mouse tail vein injection 25ml/kg respectively, and control group gives 0.9% sodium chloride injection of equivalent.Observed for two weeks continuously, record is tried situations such as mouse behavior, activity, food ration, body weight, ight soil, death, and not dead mouse is put to death after two weeks and performs an autopsy on sb.
4.2 test-results:
Group Administration volume (ml/kg) Number of animals (only) Dead animal number (only) Maximum dosage-feeding (mg/kg) Be equivalent to the clinical application multiple
Control group 25.0 20 0 / /
Sample sets
Compound 1 25.0 20 0 2500 600
Compound 2 25.0 20 0 2500 600
Compound 3 25.0 20 0 2500 600
Compound 4 25.0 20 0 2500 600
Compound 5 25.0 20 0 2500 600
Compound 7 25.0 20 0 2500 600
Compound 8 25.0 20 0 2500 600
Compound 4 and compound 5 compositions 25.0 20 0 2500 600
100mg/ml×25ml/kg (2500mg/kg+250mg/60kg)
(20 mouse of dosage vein single administration of 100mg/ml * 25ml/kg) saw that the mouse hair color was smooth, movable the same day, ingested, ight soil color and luster and quality be normal, with control group no significant difference relatively to press 2500mg/kg; And do not have dead in two weeks and other unusual phenomenon takes place, two groups perform an autopsy on sb after putting to death simultaneously, and each main organs (heart, liver, spleen, lung, kidney) changes through the visual inspection no abnormality seen, with control group no significant difference relatively.
4.3 conclusion (of pressure testing):
Maximum dosage-feeding test-results through the vein single administration shows: all do not have tangible toxic reaction after 160 mouse administrations, also do not have dead in two weeks.Therefore, compound 1, compound 2, compound 3, compound 4, compound 5, compound 7, compound 8, compound 4 and compound 5 compositions, once the mouse maximum dosage-feeding through intravenously administrable is 2500mg/kg, calculate by clinical adult's consumption every day 250mg/60kg, then be equivalent to 600 times of clinical adult's consumption.
Two, pharmacodynamic study
1. material
1.1 medicine: the composition of compound 1, compound 4, compound 5, compound 8, compound 4 and compound 5 is provided lot number: 20030816 by Jiangxi QingFeng Pharmacy Co., Ltd, high dosage: 300mg/kg, middle dosage: 150mg/kg, low dosage: 75mg/kg, all fresh at every turn preparation.
Injection potassium sodium dehydroandroan drographolide succinate (14-deshydroxy-11.12-two dehydrogenations rographolide-3.9-disuccinic acid half ester k-na salt), Chongqing Yaoyou Pharmaceutical Co., Ltd., lot number: 20030509.
1.2 animal: mouse, body weight 22-25g; The Wistar rat, body weight 150-200g; Rabbit 2.5-3.0kg, all the male and female dual-purpose is provided by Jiangxi QingFeng Pharmacy Co., Ltd's Experimental Animal Center.Animal occupancy permit: SKYX (Jiangxi) 2003-0001.
1.3 reagent: intracellular toxin 10EU/ props up, Nat'l Pharmaceutical ﹠ Biological Products Control Institute; 2.4-dinitrophenol(DNP), Shanghai chemical reagent factory, lot number: 20030312; Nutrient agar medium, Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
1.4 bacterial strain; Streptococcus aureus, intestinal bacteria, streptococcus pneumoniae provide by Jiangxi Medical College.
1.5 testing circumstance: temperature: 25 ± 3 ℃, humidity: 45-65%.
2. experimental technique and conclusion
2.1 refrigeration function
2.1.1 intracellular toxin is caused the influence of fever in rabbits
Test preceding 2 day every day and survey rabbit body temperature 1 time, select body temperature at 38.0-39.5 ℃, and self body temperature changes less than 85 of 0.3 ℃ rabbit, 2.5-3.0kg, male and female half and half, be divided into 17 groups at random, every group 5, one group in rabbit left side ear tissue edge intravenous injection physiological saline, and two groups in rabbit left side auricular vein injection potassium sodium dehydroandroan drographolide succinate 150mg/kg, and three to 17 groups respectively at rabbit left side ear vein injection compound 1, compound 4, compound 5, the composition of compound 8 and compound 4 and compound 5, high dosage: 300mg/kg, middle dosage: 150mg/kg, low dosage: 75mg/kg, each is organized volumetric injection and is 5ml/kg.Basal body temperature when before administration, measuring a body temperature and doing zero, after the administration immediately in rabbit right auricular vein injection intracellular toxin 200EU/kg, the body temperature when measuring 1h, 2h after the administration, 3h, 4h, 6h.(seeing the following form)
Fervescence (℃)
Dosage 1h 2h 3h 4h 6h
The physiological saline control group / 1.58±0.18 1.72±0.22 1.68±0.16 1.28±0.15 0.88±0.16
The injection potassium sodium dehydroandroan drographolide succinate 150 0.72±0.16 1.10±0.22 1.52±0.24 1.25±0.28 1.23±0.23
Compound 1 300 0.18±0.12 0.22±0.15 0.20±0.14 0.16±0.11 0.15±0.12
150 0.58±0.21 0.62±0.18 0.52±0.23 0.48±0.13 0.42±0.11
75 1.23±0.25 1.25±0.26 0.95±0.19 0.82±0.20 0.52±0.15
Compound 4 300 0.23±0.15 0.31±0.13 0.46±0.17 0.69±0.16 0.51±0.13
150 0.62±0.22 0.68±0.19 0.46±0.12 0.36±0.13 0.32±0.11
75 1.18±0.23 1.25±0.26 0.86±0.22 0.68±0.20 0.43±0.12
Compound 5 300 0.32±0.18 0.45±0.22 0.58±0.25 0.39±0.20 0.30±0.16
150 0.68±0.23 0.79±0.22 0.86±0.17 0.48±0.19 0.36±0.18
75 1.16±0.23 1.28±0.27 0.88±0.22 0.62±0.19 0.48±0.13
Compound 8 300 0.26±0.16 0.48±0.21 0.62±0.22 0.72±0.19 0.38±0.12
150 0.57±0.22 0.66±0.18 0.71±0.22 0.49±0.14 0.45±0.12
75 1.12±0.25 1.15±0.26 0.78±0.24 0.46±0.16 0.38±0.15
The composition of compound 4 and compound 5 300 0.25±0.17 0.46±0.21 0.64±0.22 0.49±0.18 0.36±0.16
150 0.63±0.23 0.76±0.19 0.78±0.21 0.52±0.17 0.49±0.16
75 1.21±0.26 1.32±0.28 0.88±0.24 0.76±0.16 0.58±0.17
2.1.2 the result shows: the composition 300mg/kg and the 150mg/kg of thing 5, compound 8, compound 4 and compound 5 in compound 1, compound 4, the change, fever in rabbits due to the intracellular toxin is all had good refrigeration function, and 75mg/kg is not obvious to refrigeration function.
2.2 anti-inflammatory action
2.2.1 egg white is caused the swollen influence of rat foot
85 of rats, 180-210g, male and female half and half, be divided into 17 groups at random, every group 5, one group of intravenous injection physiological saline, two groups of intravenous injection potassium sodium dehydroandroan drographolide succinate 200mg/kg, three, four, five groups of difference intravenous injection compounds 1,400mg/kg, 200mg/kg, 100mg/kg, six, seven, eight groups of difference intravenous injection compounds 4,400mg/kg, 200mg/kg, 100mg/kg, nine, ten, 11 groups of difference intravenous injection compounds 5,400mg/kg, 200mg/kg, 100mg/kg, 12,13,14 difference intravenous injection compounds 8,400mg/kg, 200mg/kg, 100mg/kg, 15,16,17 groups of compositions of distinguishing intravenous injection compound 4 and compound 5,400mg/kg, 200mg/kg, 100mg/kg, each is organized volumetric injection and is 0.1ml/10g.Before the administration with the right ankle joint flooding boundary of marking pen mark rat, the Volume of Displacement method measure cause for 1 time scorching before the right sufficient Volume of Displacement of rat, after the administration immediately only in the right back sole SC of rat fresh albumen 0.1ml/.Rat foot Volume of Displacement when measuring 1h, 2h after the administration, 3h, 5h.(seeing the following form)
Group Dosage (mg/kg) Volume of Displacement
1h 2h 3h 5h
The physiological saline control group / 0.75±0.20 0.78±0.15 0.58±0.09 0.36±0.08
The injection potassium sodium dehydroandroan drographolide succinate 200 0.56±0.11 0.59±0.08 0.42±0.07 0.33±0.05
Compound 1 400 0.25±0.08 0.27±0.06 0.23±0.07 0.15±0.05
200 0.55±0.07 0.55±0.07 0.43±0.04 0.30±0.07
100 0.76±0.13 0.72±0.13 0.56±0.08 0.36±0.05
Compound 4 400 0.28±0.07 0.29±0.06 0.23±0.07 0.16±0.05
200 0.53±0.07 0.54±0.07 0.46±0.04 0.32±0.07
100 0.78±0.14 0.75±0.13 0.58±0.08 0.39±0.05
Compound 5 400 0.26±0.08 0.28±0.07 0.23±0.07 0.16±0.05
200 0.60±0.06 0.65±0.08 0.53±0.06 0.48±0.05
100 0.86±0.12 0.82±0.13 0.63±0.07 0.43±0.04
Compound 8 400 0.23±0.07 0.25±0.08 0.22±0.07 0.18±0.06
200 0.57±0.07 0.54±0.07 0.41±0.06 0.36±0.05
100 0.72±0.12 0.73±0.12 0.63±0.07 0.42±0.04
The composition of compound 4 and compound 5 400 0.24±0.07 0.26±0.08 0.23±0.07 0.19±0.06
200 0.55±0.07 0.53±0.07 0.48±0.06 0.42±0.04
100 0.73±0.12 0.75±0.12 0.64±0.07 0.48±0.05
2.2.2 conclusion: compound 1, compound 4, compound 5, compound 8 and compound 4 have good anti-inflammatory action with the composition of compound 5.
2.3 antibacterial tests:
2.3.1 extracorporeal bacteria inhibitor test:
With physiological saline the composition of compound 1, compound 4, compound 5, compound 8, compound 4 and compound 5 is made into 2% injection liquid, make starting point concentration after the filtering with microporous membrane degerming, reducing by half with injection physiological saline is diluted to 1/2,1/4,1/8,1/6,1/32 concentration again.With injection physiological saline the injection potassium sodium dehydroandroan drographolide succinate is mixed with 2% injection liquid, make starting point concentration after the filtration sterilization, reduce by half with physiological saline again and be diluted to 1/2,1/4,1/8,1/16,1/32 concentration, draw 1ml respectively in sterile test tube, add the 9ml nutrient agar medium, shake up, in 37 ℃ of constant incubators, cultivate 24h behind the inoculated bacteria and observe.
1/4 + + +
1/8 + + +
1/16 + + +
1/32 + + +
Compound 4 and compound 5 compositions 1/1 - - -
1/2 - - -
1/4 + + +
1/8 + + +
1/16 + + +
1/32 + + +
2.3.2 result: compound 1, compound 4, compound 5, compound 8, compound 4 all have stronger anti-microbial effect with the composition of compound 5.
Embodiment 9
The stability test of compound 1-11
1, instrument and reagent
Instrument TV-1800SPC ultraviolet-visible pectrophotometer (Beijing Puxi General Instrument Co., Ltd).
Reagent is analytical pure; Sample is provided by Jiangxi QingFeng Pharmacy Co., Ltd.
2, constant temperature accelerated test: compound 1-11 sample is placed in the 37-40 ℃ of constant temperature accelerated tests case,, measures content as follows in sampling 0 month, 1 month, 2 months, 3 months, 6 months pitch times.
3, measuring method
3.1 the preparation of reference substance (compound 1-11, purity is all more than 99%) solution: precision takes by weighing the reference substance that is dried to constant weight at 105 ℃, adds ethanol and makes the solution that every 1ml contains 1mg.
3.2 the preparation of sample (compound 1-11) solution: precision takes by weighing sample 50mg, puts in the 50ml volumetric flask, is diluted to scale, shakes up with Diluted Alcohol.
3.3 assay method: precision is measured reference substance solution and each 2ml of need testing solution, place the 10ml measuring bottle respectively, put in 20 ℃ of water-baths, accurate adding 2%3,5-dinitrobenzoic acid ethanolic soln 2ml shakes up, accurately again add potassium hydroxide solution (2ml of 1.22g → 100ml), shakes up to scale with 60% alcohol dilution, placed 5 minutes, with the reagent corresponding is blank, measures optical density according to spectrophotometry (appendix VB of Chinese Pharmacopoeia version in 2000) respectively at the wavelength place of 540nm, calculates.
Constant temperature accelerated test result
Figure C20051003856100241
Conclusion: the constant temperature accelerated test through 6 months proves: compound 1-11 chemical property is stable.
Embodiment 10
Take by weighing compound 4.25g, with the about 800ml dissolving of water for injection, add 0.1% gac and stirred 10 minutes, filter, add the injection water to 1000ml, filter, regulate the pH value to 4.5-6.5 with 10% sodium hydroxide solution, embedding (small-volume injection, specification is that 2ml/ props up, 5ml/ props up, 10ml/ props up), 100 ℃, sterilization in 30 minutes, clarity test, packing, promptly.
Usage and dosage: intramuscularly: the 50-100mg that is grown up a time, 2-3 time on the one, children's is cut down according to the circumstance or is followed the doctor's advice.Intravenous drip: 250-500mg on the one adds among 5% glucose injection or the sodium chloride injection 250-500ml and instils; Children's is cut down according to the circumstance or is followed the doctor's advice.
Embodiment 11
Take by weighing compound 4, compound 5, each 1g with the about 800ml dissolving of glucose isotonic solution, adds 0.1% gac and stirred 10 minutes, filter, add the glucose isotonic solution to 1000ml, filter, regulate the pH value to 4.5-6.5 with 10% dissolution of sodium hydroxide, embedding (high-capacity injection, specification is 50ml/ bottle, 100ml/ bottle, 250ml/ bottle, 500ml/ bottle) 100 ℃, sterilization in 30 minutes, clarity test, packing, promptly.
Usage and dosage: intravenous drip: 250-500mg on the one.Children's is cut down according to the circumstance or is followed the doctor's advice.
Embodiment 12
Take by weighing compound 4.25g, add injection water 600ml, stirring and dissolving, add 25g N.F,USP MANNITOL, after the stirring and dissolving, add the injection water to 1000ml, mixing, with 0.22 μ m filtering with microporous membrane, gained solution is sub-packed in the 7ml cillin bottle, every bottle of 2ml, capping plug, put into Freeze Drying Equipment, carry out lyophilize, get compound 4 freeze-dried powders (every 50mg) according to the freeze-drying curve that designs.
Usage and dosage: intramuscularly: the 50-100mg that is grown up a time, 2-3 time on the one, children's is cut down according to the circumstance or is followed the doctor's advice, intravenous drip: 250-500mg on the one, add among 5% glucose injection or the sodium chloride injection 250-500ml and instil, children's is cut down according to the circumstance or is followed the doctor's advice.
Embodiment 13
Take by weighing compound 4.25g,, add 0.1% gac and stirred 10 minutes with the about 800ml dissolving of water for injection, filter, add the injection water to 1000ml, filter, after the adding sucrose 200g stirring and dissolving, regulate the pH value to 4.5-6.5 with 10% sodium hydroxide solution, filter, the filtrate can in 10ml glass bottle, 100 ℃, sterilization in 30 minutes, clarity test, packing, promptly.
Usage and dosage: oral: one time 1, three times on the one.

Claims (8)

1, following general formula (I) or (II) sulfonated derivative of andrographolide of expression,
Each group definition is as follows in the general formula (I): R 1 R 2 R 3 R 4 Compound 1 compound 2 compounds 3 compounds 4 compounds 5 H SO 3H SO 3H H SO 3H SO 3H H SO 3H SO 3H H OH OH ONa ONa R 3＝R 4 O O O
Figure C2005100385610002C2
Each group definition is as follows in the general formula (II):
。
2, the general formula of claim 1 (I) or (II) mixture of sulfonated derivative of andrographolide of expression, described mixture are selected from two or more in the sulfonated derivative of andrographolide of general formula (I), (II) expression.
3, the general formula of claim 2 (I) or (II) mixture of the sulfonated derivative of andrographolide of expression, described mixture is selected from two or more in compound 1, compound 4, compound 5, the compound 8.
4, a kind of pharmaceutical composition, the mixture and the pharmaceutically acceptable carrier of the sulfonated derivative of andrographolide of expression are formed by the general formula (I) of the general formula (I) of claim 1 or sulfonated derivative of andrographolide of (II) representing or claim 2 or (II).
5, the pharmaceutical composition of claim 4, the mixture and the water for injection of the sulfonated derivative of andrographolide of expression are formed by the general formula (I) of the general formula (I) of claim 1 or sulfonated derivative of andrographolide of (II) representing or claim 2 or (II).
6, the pharmaceutical composition of claim 4, the mixture and the N.F,USP MANNITOL freeze-dried powder auxiliary material of the sulfonated derivative of andrographolide of expression are formed by the general formula (I) of the general formula (I) of claim 1 or sulfonated derivative of andrographolide of (II) representing or claim 2 or (II).
7, the pharmaceutical composition of claim 4, the mixture and the oral preparations auxiliary material of the sulfonated derivative of andrographolide of expression are formed by the general formula (I) of the general formula (I) of claim 1 or sulfonated derivative of andrographolide of (II) representing or claim 2 or (II).
8, the general formula of claim 1 (I) or (II) sulfonated derivative of andrographolide of expression or the general formula (I) of claim 2 or (II) application in the mixture of the sulfonated derivative of andrographolide of expression, anti-inflammatory analgesic or the antibacterials in preparation.
CNB2005100385611A 2005-03-25 2005-03-25 Sulfonated derivative of andrographolide and combination of medication Expired - Lifetime CN1290838C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100385611A CN1290838C (en) 2005-03-25 2005-03-25 Sulfonated derivative of andrographolide and combination of medication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100385611A CN1290838C (en) 2005-03-25 2005-03-25 Sulfonated derivative of andrographolide and combination of medication

Publications (2)

Publication Number Publication Date
CN1687049A CN1687049A (en) 2005-10-26
CN1290838C true CN1290838C (en) 2006-12-20

Family

ID=35305091

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100385611A Expired - Lifetime CN1290838C (en) 2005-03-25 2005-03-25 Sulfonated derivative of andrographolide and combination of medication

Country Status (1)

Country Link
CN (1) CN1290838C (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102382083B (en) * 2010-09-01 2015-07-15 天津天士力现代中药资源有限公司 Preparation method of andrographolide
CN102127062B (en) * 2010-12-29 2013-06-19 中国药科大学 Substituted isoandrographolide derivative, preparation method and medical application thereof
CN103159708A (en) * 2012-04-12 2013-06-19 江西青峰药业有限公司 Once preparation method of composite of 17-hydrogen-9-dehydro-andrographolidume-3-sodium (or potassium) disulfate and 17-hydrogen-9-dehydro-andrographolidume-19-sodium (or potassium) disulfate, and purposes of medicine prepared by the same
CN103159713A (en) * 2012-04-12 2013-06-19 江西青峰药业有限公司 Composite of 17-hydrogen-9-dehydro-andrographolidume-3, 19-sodium (or potassium) disulfate and 17-hydrogen-9-dehydro-andrographolidume-19-sodium (or potassium) disulfate, and purposes of medicine prepared by the same
CN103159715B (en) * 2012-04-12 2015-08-05 江西青峰药业有限公司 17-hydrogen-9-dehydrogenation rographolide-14-sulfuric ester compound, preparation method and prepare pharmaceutical use
CN103156840B (en) * 2012-04-12 2015-07-08 江西青峰药业有限公司 Once preparation method of composite of 17-hydrogen-9-dehydro-andrographolidume-3-sodium (or potassium) disulfate and 17-hydrogen-9-dehydro-andrographolidume-3, 19-sodium (or potassium) disulfate, and purposes of prepared medicine
CN103145665B (en) * 2012-04-12 2014-12-31 江西青峰药业有限公司 17-hydro-9-dehydro-14,17-cyclo-andrographolide-19-sulphate and its preparation method and use in drug preparation
CN103159712A (en) * 2012-04-12 2013-06-19 江西青峰药业有限公司 Compound of 17-hydrogen-9-dehydrogenation andrographolide-3-sulphate sodium (or potassium) and 17-hydrogen-9-dehydrogenation andrographolide-3, 19-disulfate sodium (or potassium) and preparation drug purposes thereof
CN103159716B (en) * 2012-04-12 2015-08-05 江西青峰药业有限公司 17-hydrogen-9-dehydrogenation rographolide-3-sulfuric ester compound, preparation method and prepare pharmaceutical use
CN103159720B (en) * 2012-04-12 2014-12-31 江西青峰药业有限公司 8-epi-isoandrographolidume-19-sulfate, preparation method and purposes of prepared medicine
CN103145657B (en) * 2012-04-12 2015-12-02 江西青峰药业有限公司 17-hydrogen-9-dehydrogenation rographolide compound, preparation method and prepare pharmaceutical use
CN103159714B (en) * 2012-04-12 2015-08-05 江西青峰药业有限公司 17-hydrogen-9-dehydrogenation rographolide-19-sulfuric ester compound, preparation method and prepare pharmaceutical use
CN103145659A (en) * 2012-04-12 2013-06-12 江西青峰药业有限公司 Composition of sodium (or potassium) 17-hydro-9-dehydroandrographolide-3-sulphate, sodium (or potassium) 17-hydro-9-dehydroandrographolide-19-sulphate and sodium (or potassium) 17-hydro-9-dehydroandrographolide-3,19-disulfate, and use of the composition in drug preparation
CN103145658A (en) * 2012-04-12 2013-06-12 江西青峰药业有限公司 One-step preparation method of composition of sodium (or potassium) 17-hydro-9-dehydroandrographolide-3-sulphate, sodium (or potassium) 17-hydro-9-dehydroandrographolide-19-sulphate and sodium (or potassium) 17-hydro-9-dehydroandrographolide-3,19-disulfate, and use of the composition in drug preparation.
CN103159717B (en) * 2012-04-12 2015-11-25 江西青峰药业有限公司 17-hydrogen-9-dehydrogenation rographolide-3,19-di-sulfate compound, preparation method and prepare pharmaceutical use
CN103159711B (en) * 2012-04-12 2015-03-11 江西青峰药业有限公司 Once preparation method of composite of 17-hydrogen-9-dehydro-andrographolidume-3, 19-sodium (or potassium) disulfate and 17-hydrogen-9-dehydro-andrographolidume-19-sodium (or potassium) disulfate, and purposes of prepared medicine
CN103156841A (en) * 2012-04-12 2013-06-19 江西青峰药业有限公司 Compound of 17-hydrogen-9-dehydrogenation andrographolide-3-sulphate sodium (or potassium) and 17-hydrogen-9-dehydrogenation andrographolide-19-sulphate sodium (or potassium) and preparation drug purposes thereof
CN103159721B (en) * 2012-04-12 2014-12-31 江西青峰药业有限公司 8-epi-12-epi-isoandrographolidume-19-sulfate, preparation method and purposes of prepared medicine
CN103622951B (en) * 2012-08-27 2015-09-30 黑龙江佰彤儿童药物研究有限公司 Lian Bizhi oral liquid its preparation method
CN104119253B (en) * 2013-04-24 2015-12-09 江西青峰药业有限公司 A pharmaceutical composition of andrographolide derivatives and its preparation method and application
CN104119251B (en) * 2013-04-24 2015-12-09 江西青峰药业有限公司 9-dehydro-andrographolide-17-sulfonic acid-16-carboxylic acid or its salt, preparation method and pharmaceutical use thereof
CN109364063B (en) * 2018-11-14 2021-05-11 株洲千金药业股份有限公司 Compound with antibacterial effect and application thereof in preparation of antibacterial drugs
CN112778168A (en) * 2019-11-08 2021-05-11 江西青峰药业有限公司 Method for preparing andrographolide-19-sulfate-16-sodium carboxylate
CN112826817B (en) * 2019-11-22 2024-07-09 江西青峰药业有限公司 Medicinal composition of andrographolide sulfonate and preparation method thereof
CN112830914A (en) * 2019-11-22 2021-05-25 江西青峰药业有限公司 A kind of pharmaceutical composition of andrographolide sulfonate and preparation method thereof
CN113087618A (en) * 2019-12-23 2021-07-09 江西青峰药业有限公司 Method for preparing andrographolide derivatives by using industrial chromatography
CN113121483B (en) * 2019-12-31 2024-11-12 江西青峰药业有限公司 A method for preparing andrographolide derivatives using industrial chromatography technology
CN116763777A (en) * 2022-03-09 2023-09-19 四川育强本草生物技术有限公司 Use of 17-hydro-9-dehydroandrographolide-19-sulfate sodium in the preparation of drugs for treating dairy cow mastitis

Also Published As

Publication number Publication date
CN1687049A (en) 2005-10-26

Similar Documents

Publication Publication Date Title
CN1290838C (en) Sulfonated derivative of andrographolide and combination of medication
CN107793400B (en) Pyridine compound and application thereof in preparation of drugs for treating liver diseases
ES2575981T3 (en) Cyclic peptide derived from Nonomuraea sp., Process for its production, and pharmaceutical composition for the prevention or treatment of a disease related to mycobacteria comprising the same
CN1285586C (en) Tectoridin isoflavone derivatives, their preparation process, and anti-virus medicines with tectoridin isoflavone derivatives as active components
CN101040915A (en) Method for preparing a Shuanhuanglian injection and the component detecting method
CN114315924B (en) A kind of phenolic glycoside compound eyrein F, its preparation method and application
CN110407847A (en) A kind of azaphilones compound obtained from Aspergillus terreus and its preparation and application
KR20240093977A (en) Crystalline form of isobutyrate nucleoside compound and method for producing the same
CN105111253B (en) A kind of method for extracting separation gangliosides
CN103923158A (en) A-ring polyoxygenated glycyrrhetinic acid derivatives, preparation method and use thereof
CN104262443B (en) The preparation method and application of polyhydroxy sterol class monomeric compound
CN1566136A (en) Pasqueflower notoginsenosides and extraction method, medicinal uses and pharmaceutical preparation thereof
CN1118471C (en) Medicine containing tan matter caesalpinia extract
CN1357327A (en) Carbazolyl alkaloid anticarcinogen and its prepn
CN101077341A (en) Application of aurantio-obtusifolin or its derivates in preparing hypolipidemic drug
CN101036647A (en) Medical composition having anti-inflammatory and anti-infectious function
CN1261372A (en) Natural antitumor or antiviral substances and use of the same
CN101077873A (en) Novel NEO-clerodane type diterpene compound and application thereof
CN1071929A (en) Preparation method of phosphoric acid and sulfonate of epipodophyllotoxin glycoside
CN1305870C (en) Novel flavane derivative and its preparation method and uses
CN1785295A (en) Quality control method of cbinese medicinal preparation
CN114436884A (en) A kind of burdock ceramide compound and its preparation method and application
CN1274301C (en) Application of alpha benzyl, beta benzyl and gamma butyrolactone for preparing medicine of lowering blood sugar
CN111166733A (en) Resveratrol-fatty acid coupling compound and medical application thereof
CN1837229A (en) Clarithromycin derivatives and its preparation process and pharmaceutical application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20081205

Address after: Shahe Industrial Park, Ganzhou, Jiangxi

Patentee after: JIANGXI QINGFENG PHARMACEUTICAL Co.,Ltd.

Address before: Jiangxi city of Ganzhou province Zhanggong District of Shahe Industrial Park

Patentee before: Tang Chunshan

ASS Succession or assignment of patent right

Owner name: JIANGXI QINGFENG PHARMACY CO., LTD.

Free format text: FORMER OWNER: TANG CHUNSHAN

Effective date: 20081205

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20061220